Format

Send to

Choose Destination
Proc Natl Acad Sci U S A. 2014 Jun 24;111(25):9157-62. doi: 10.1073/pnas.1317630111. Epub 2014 Jun 9.

Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer.

Author information

1
Department of Molecular and Medical Genetics and.
2
Oregon Stem Cell Center, Oregon Health and Science University, Portland, OR 92739;
3
Oncotide Pharmaceuticals, Inc., Research Triangle Park, NC 27709; and.
4
Oncotide Pharmaceuticals, Inc., Research Triangle Park, NC 27709; andDivision of Hematology, Department of Medicine, Duke University Medical Center, Durham, NC 27710.
5
Department of Molecular and Medical Genetics and searsr@ohsu.edu.

Abstract

The transcription factor c-MYC is stabilized and activated by phosphorylation at serine 62 (S62) in breast cancer. Protein phosphatase 2A (PP2A) is a critical negative regulator of c-MYC through its ability to dephosphorylate S62. By inactivating c-MYC and other key signaling pathways, PP2A plays an important tumor suppressor function. Two endogenous inhibitors of PP2A, I2PP2A, Inhibitor-2 of PP2A (SET oncoprotein) and cancerous inhibitor of PP2A (CIP2A), inactivate PP2A and are overexpressed in several tumor types. Here we show that SET is overexpressed in about 50-60% and CIP2A in about 90% of breast cancers. Knockdown of SET or CIP2A reduces the tumorigenic potential of breast cancer cell lines both in vitro and in vivo. Treatment of breast cancer cells in vitro or in vivo with OP449, a novel SET antagonist, also decreases the tumorigenic potential of breast cancer cells and induces apoptosis. We show that this is, at least in part, due to decreased S62 phosphorylation of c-MYC and reduced c-MYC activity and target gene expression. Because of the ubiquitous expression and tumor suppressor activity of PP2A in cells, as well as the critical role of c-MYC in human cancer, we propose that activation of PP2A (here accomplished through antagonizing endogenous inhibitors) could be a novel antitumor strategy to posttranslationally target c-MYC in breast cancer.

KEYWORDS:

breast cancer therapy; phosphatase activator

PMID:
24927563
PMCID:
PMC4078832
DOI:
10.1073/pnas.1317630111
[Indexed for MEDLINE]
Free PMC Article

Publication types, MeSH terms, Substances, Secondary source ID, Grant support

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center